Bacteremia Staph clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

    open to eligible people ages 18 years and up

    Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus

    Los Angeles, California and other locations

Our lead scientists for Bacteremia Staph research studies include .

Last updated: